GlaxoSmithKline PLC (GSK) Tuesday said it will push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials. The British company said top-line data from seven of eight late-stage Phase III clinical studies had now been received and, when taken together, support advancing albiglutide toward regulatory filings. The new injectable medicine belongs to the same class of GLP-1 therapies as Denmark’s Novo Nordisk A/S (NOVO-B.KO) Victoza, which was approved in Europe in 2009 and in the U.S. a year later, and Byetta from Amylin Pharmaceuticals (AMLN) and Eli Lilly (LLY), which was the first drug of the type. Full Text
Comments are closed.